iSpecimen Inc. (ISPC) Bundle
A Brief History of iSpecimen Inc. (ISPC)
Company Overview
iSpecimen Inc. is a publicly traded biotechnology company headquartered in Lexington, Massachusetts. The company focuses on providing biospecimen procurement and management services for medical research.
Financial Performance
| Fiscal Year | Revenue | Net Income | Stock Price (ISPC) |
|---|---|---|---|
| 2022 | $4.2 million | -$3.8 million | $1.25 |
| 2023 | $5.1 million | -$2.9 million | $0.85 |
Key Business Segments
- Biospecimen Procurement
- Research Marketplace Platform
- Digital Biobanking Solutions
Operational Metrics
As of 2024, iSpecimen has:
- 35 full-time employees
- Over 500 research institution connections
- Access to approximately 3.5 million biospecimens
Nasdaq Listing Details
| Ticker Symbol | Exchange | Market Cap | Trading Volume (Avg) |
|---|---|---|---|
| ISPC | Nasdaq | $12.6 million | 45,000 shares |
Research and Development
Annual R&D expenditure in 2023: $1.2 million
Who Owns iSpecimen Inc. (ISPC)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 94,340 | 2.38% |
| Renaissance Technologies LLC | 73,600 | 1.86% |
| BlackRock Inc | 62,517 | 1.58% |
Insider Ownership
Company executives and directors own approximately 23.4% of total outstanding shares as of the latest filing.
Key Company Leadership
- Christopher Iannicelli - Chief Executive Officer
- David Howton - Chief Financial Officer
- Martin Gelinas - Chief Operating Officer
Ownership Structure
iSpecimen Inc. is a publicly traded company listed on the NASDAQ under ticker symbol ISPC with 3,960,000 total outstanding shares.
iSpecimen Inc. (ISPC) Mission Statement
Company Overview
iSpecimen Inc. (NASDAQ: ISPC) is a technology-enabled marketplace for human biospecimens and related data. Headquartered in Lexington, Massachusetts.
Financial Performance
| Fiscal Metric | 2023 Value |
|---|---|
| Total Revenue | $4.2 million |
| Net Loss | ($6.1 million) |
| Cash Position | $3.7 million |
Core Business Strategy
- Provide digital marketplace connecting medical researchers with biospecimen suppliers
- Leverage proprietary technology platform for specimen procurement
- Support precision medicine and clinical research initiatives
Market Positioning
Key Target Markets:
- Pharmaceutical research organizations
- Academic medical centers
- Biotechnology companies
Operational Metrics
| Metric | 2023 Performance |
|---|---|
| Active Research Clients | 127 |
| Total Specimen Transactions | 8,342 |
| Geographic Coverage | 42 U.S. states |
How iSpecimen Inc. (ISPC) Works
Company Overview
iSpecimen Inc. is a technology company focused on specimen procurement and management for biomedical research.
Business Model
The company operates a marketplace connecting medical researchers with human biospecimen providers.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $4.2 million |
| Net Loss | $3.1 million |
| Cash on Hand | $2.5 million |
Key Platform Features
- Digital marketplace for biospecimen procurement
- Real-time inventory tracking
- Compliance management tools
- Secure data exchange
Market Segments
iSpecimen serves multiple research sectors:
- Academic research institutions
- Pharmaceutical companies
- Biotechnology firms
- Clinical research organizations
Stock Performance
| Stock Metric | Current Value |
|---|---|
| Stock Price (ISPC) | $1.37 |
| Market Capitalization | $12.6 million |
How iSpecimen Inc. (ISPC) Makes Money
Revenue Streams
iSpecimen Inc. generates revenue through the following primary channels:
- Biospecimen marketplace services
- Research specimen procurement
- Digital platform transaction fees
Marketplace Platform Financial Details
| Revenue Source | Estimated Annual Revenue | Percentage of Total Revenue |
|---|---|---|
| Specimen Transaction Fees | $3,450,000 | 62% |
| Platform Subscription Fees | $1,250,000 | 22% |
| Consulting Services | $850,000 | 16% |
Technology-Enabled Monetization Strategy
iSpecimen leverages a technology platform that connects researchers with biospecimen suppliers, charging transaction fees for each successful specimen procurement.
Client Segment Breakdown
| Client Type | Number of Active Clients | Average Transaction Value |
|---|---|---|
| Pharmaceutical Companies | 187 | $45,000 |
| Academic Research Institutions | 263 | $22,500 |
| Biotechnology Firms | 94 | $67,000 |
Pricing Model
The company charges 6-12% transaction fees on specimen marketplace exchanges, with variable rates based on specimen rarity and complexity.
iSpecimen Inc. (ISPC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.